Overview

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.
Phase:
Phase 3
Details
Lead Sponsor:
Nihon Pharmaceutical Co., Ltd
Treatments:
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rho(D) Immune Globulin